1:26:15

Updates on MDS Classifications

1:38:53

MDS Support Group Webinar

56:15

The Evolving Role of NGS and Measurable Residual Disease in CLL/SLL and AML

20:06

2024 FSS at ASH - Debate III: Treatment of HR-MDS (in 2024)

59:21

Clinical Utility of NGS in Lymphoid Malignancies

7:01

2024 FSS at ASH - Challenges in MDS

27:15

2024 FSS at ASH - Debate II: A Role for Anti-Inflammatory Treatment

24:08

2024 FSS at ASH - Patient Discussion - Case 2 & 3: LR-MDS with Isolated Cytopenias